AlphaMaven AlphaMaven

CVC eyes co-investment partners for €10.9bn Recordati buyout

Reported by Private Equity Wire ·Bloomberg
Apr 10, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • CVC Capital Partners is actively syndicalizing a €10.9bn acquisition of Italian pharmaceutical firm Recordati, with targeted equity contributions of €5.5bn–€6bn positioning this among Europe's largest recent leveraged buyouts.
  • • The firm has initiated early-stage discussions with sovereign wealth funds and institutional investors including Abu Dhabi Investment Authority, GIC, Caisse de dépôt et placement du Québec, and Groupe Bruxelles Lambert to secure co-investment commitments.
  • • CVC's offer values Recordati at €52 per share and is being pursued through the firm's latest flagship fund, which already maintains an existing stake in the Milan-listed pharmaceutical company.
  • • Strategic portfolio optimization is anticipated post-acquisition, with potential divestments of non-core assets including Recordati's rare diseases division under consideration by CVC management.
  • • All discussions remain preliminary with no certainty of finalized co-investment arrangements; all parties have declined to comment on the transaction status.
Summary
CVC Capital Partners is pursuing a €10.9bn takeover of Recordati, the Milan-listed Italian pharmaceutical company, and is actively seeking co-investment partners to syndicate a significant portion of the required equity. According to Bloomberg, CVC has held preliminary discussions with a range of institutional and sovereign wealth investors, including Abu Dhabi Investment Authority, GIC, Caisse de dépôt et placement du Québec, and Groupe Bruxelles Lambert, to secure capital commitments for the transaction.

The deal structure requires equity contributions in the region of €5.5bn to €6bn, making it one of the largest leveraged buyouts executed in Europe in recent years. CVC is pursuing the acquisition through its latest flagship fund, which already holds a meaningful stake in Recordati. The firm submitted its acquisition offer at €52 per share following an evaluation of alternative strategic options for its existing holding in the company.

Recordati, founded in 1926, has transformed from a family-owned pharmacy business into a diversified pharmaceutical group with operations across specialty care, primary care, consumer health, and rare disease treatments. The company's established product portfolio includes therapies such as Zanidip for hypertension and Eligard for prostate cancer, complemented by a chemicals division that supplies active pharmaceutical ingredients to the broader pharmaceutical industry. Post-acquisition, CVC is expected to pursue portfolio optimization opportunities, with potential divestments of non-core assets such as the rare diseases division under review.

Discussions between CVC and prospective co-investors remain at an early stage, with no certainty that binding co-investment arrangements will be finalized. All parties involved have declined to provide comment on the transaction's status or timeline.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

2 outlets

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Private Equity Wire CVC eyes co-investment partners for €10.9bn Recordati buyout Bloomberg CVC Said to Seek Partners for €10.9 Billion Recordati Deal